Recent News

• 09.17.2025 - Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer
• 09.17.2025 - Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer
• 09.17.2025 - Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer
• 09.17.2025 - Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer
• 09.09.2025 - Sean Lee
• 09.09.2025 - Sean Lee
• 09.05.2025 - Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
• 09.05.2025 - Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
• 09.05.2025 - Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
• 09.03.2025 - Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series

Recent Filings

• 08.29.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 08.29.2025 - 8-K Current report
• 08.29.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.21.2025 - 8-K Current report
• 08.19.2025 - 8-K Current report
• 08.19.2025 - EX-99.1 EX-99.1